BridgeBio Pharma (BBIO) Amortizatization of Intangibles (2018 - 2026)

BridgeBio Pharma has reported Amortizatization of Intangibles for 8 years, with the latest figure at $27.5 million in Q2 2025.

• Quarterly Amortizatization of Intangibles rose 1546.58% year-over-year to $27.5 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $65.2 million (up 713.81% YoY) and the FY2024 annual result came in at $15.8 million, up 76.97% from the prior year.
• Amortizatization of Intangibles rose to $27.5 million in Q2 2025 per BBIO's latest filing, from $25.6 million in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $27.5 million in Q2 2025 and troughed at $1.2 million in Q1 2021.
• A 5-year average of $5.1 million and a median of $2.1 million in 2022 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2021 and 2025: Amortizatization of Intangibles tumbled 73.95% in 2021, then soared 1546.58% in 2025.
• Over 5 years, Amortizatization of Intangibles stood at $1.8 million in 2021, then gained by 19.92% to $2.1 million in 2022, then rose by 3.9% to $2.2 million in 2023, then surged by 374.76% to $10.4 million in 2024, then soared by 165.0% to $27.5 million in 2025.
• According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $27.5 million, $25.6 million, and $10.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.